micro-community-banner
Profile Image
  • Add Media
  • Saved

2yr
Failure of Lipid Control by PCSK9 Inhibitors in Compound Heterozygous Familial Hypercholesterolemia Complicated With Premature Myocardial Infarction: a Case Report

Failure of Lipid Control by PCSK9 Inhibitors in Compound Heterozygous Familial Hypercholesterolemia Complicated With Premature Myocardial Infarction: a Case Report

Source : https://pubmed.ncbi.nlm.nih.gov/38487640/

Familial hypercholesterolemia (FH) is a serious autosomal dominant disorder. Managing blood lipids in FH patients poses greater challenges for clinicians. Drug therapy may not always yield satisfactory results, particularly in...

The inefficacy of proprotein-converting enzymes/kexin 9 inhibitors may arise from the extensive mutations, leading to loss of low-density lipoprotein receptor activity.

Profile Image
  • Saved

2yr
PCSK9 Inhibition With Orally Administered NNC0385-0434 in Hypercholesterolaemia: a Randomised, Double-Blind, Placebo-Controlled and Active-Controlled Phase 2 Trial

PCSK9 Inhibition With Orally Administered NNC0385-0434 in Hypercholesterolaemia: a Randomised, Double-Blind, Placebo-Controlled and Active-Controlled Phase 2 Trial

Source : https://pubmed.ncbi.nlm.nih.gov/38310920/

Novo Nordisk.

The estimated treatment difference between NNC0385-0434 100 mg and evolocumab 140 mg was 3.4%.

Profile Image
  • Saved

2yr
An Inclisiran First Strategy vs Usual Care in Patients With Atherosclerosis

An Inclisiran First Strategy vs Usual Care in Patients With Atherosclerosis

Source : https://pubmed.ncbi.nlm.nih.gov/38593947/

An "inclisiran first" implementation strategy led to greater LDL-C lowering compared with usual care without discouraging statin use or raising new safety concerns.

The "inclisiran first" strategy led to significantly greater reductions in LDL-C from baseline to day 330 versus usual care.

Profile Image
  • Saved

2yr
A Wrap Up of The American College of Cardiology 2024 Scientific Session

This year’s meeting marked the 75th anniversary of ACC and included practice-changing information on the prevention, diagnosis, and treatment of the full spectrum of cardiovascular diseases. Click to access our postconference wrap-up report.

  • Saved

2yr
Cardiovascular Risk Factors and Complications in Patients With Systemic Lupus Erythematosus With and Without Nephritis: a Systematic Review and Meta-Analysis

Cardiovascular Risk Factors and Complications in Patients With Systemic Lupus Erythematosus With and Without Nephritis: a Systematic Review and Meta-Analysis

Source : https://pubmed.ncbi.nlm.nih.gov/38519060/

CRD42022314682.

Patients with systemic lupus erythematosus and lupus nephritis showed significantly higher risk of hypertension, hyperlipidemia, and type 2 diabetes compared with those without lupus nephritis.

Profile Image